| 000 | 03113nam a22005535i 4500 | ||
|---|---|---|---|
| 001 | 978-3-642-38664-0 | ||
| 003 | DE-He213 | ||
| 005 | 20140220082912.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 131004s2013 gw | s |||| 0|eng d | ||
| 020 |
_a9783642386640 _9978-3-642-38664-0 |
||
| 024 | 7 |
_a10.1007/978-3-642-38664-0 _2doi |
|
| 050 | 4 | _aRM1-950 | |
| 072 | 7 |
_aMMG _2bicssc |
|
| 072 | 7 |
_aMED071000 _2bisacsh |
|
| 082 | 0 | 4 |
_a615 _223 |
| 100 | 1 |
_aHumbert, Marc. _eeditor. |
|
| 245 | 1 | 0 |
_aPharmacotherapy of Pulmonary Hypertension _h[electronic resource] / _cedited by Marc Humbert, Oleg V. Evgenov, Johannes-Peter Stasch. |
| 264 | 1 |
_aBerlin, Heidelberg : _bSpringer Berlin Heidelberg : _bImprint: Springer, _c2013. |
|
| 300 |
_aIX, 576 p. 66 illus., 56 illus. in color. _bonline resource. |
||
| 336 |
_atext _btxt _2rdacontent |
||
| 337 |
_acomputer _bc _2rdamedia |
||
| 338 |
_aonline resource _bcr _2rdacarrier |
||
| 347 |
_atext file _bPDF _2rda |
||
| 490 | 1 |
_aHandbook of Experimental Pharmacology, _x0171-2004 ; _v218 |
|
| 505 | 0 | _aPreface.- Part I. Pulmonary hypertension: conceptual bases of the disease. Pulmonary hypertension: definition, classification, and epidemiology. Pulmonary hypertension: pathophysiology and signalling pathways. Pulmonary hypertension: pathology. Pulmonary hypertension: biomarkers. Pulmonary hypertension: animal models -- Part II. Pulmonary hypertension: established therapies. General supportive care. Calcium channel blockers. Prostacyclins. Endothelin receptor antagonists. Phosphodiesterase 5 inhibitors -- Part III. Pulmonary hypertension: novel pathways and emerging therapies Soluble guanylate cyclase stimulators. Therapeutics targeting dysregulated redox equilibrium and endothelial dysfunction (NOXs, sGC activators, GSNOR). Rho-kinase inhibitors. Serotonin transporters and serotonin receptors. PDGF inhibitors. Novel anti-proliferative strategies beyond imatinib. Immunosuppressive agents. Vasoactive peptides. Inhibitors of cGMP/cAMP metabolism (MRP4, MRP5, PDE1). Old targets re-visited. Stem cells and cell based therapy -- Part IV. Conclusions and Outlook. Pulmonary hypertension: evidence-based management in the modern era and future directions. | |
| 650 | 0 | _aMedicine. | |
| 650 | 0 | _aMedical laboratories. | |
| 650 | 0 | _aToxicology. | |
| 650 | 0 | _aPharmaceutical technology. | |
| 650 | 0 | _aInternal medicine. | |
| 650 | 0 | _aPneumology. | |
| 650 | 1 | 4 | _aBiomedicine. |
| 650 | 2 | 4 | _aPharmacology/Toxicology. |
| 650 | 2 | 4 | _aPharmaceutical Sciences/Technology. |
| 650 | 2 | 4 | _aInternal Medicine. |
| 650 | 2 | 4 | _aPneumology/Respiratory System. |
| 650 | 2 | 4 | _aLaboratory Medicine. |
| 650 | 2 | 4 | _aMolecular Medicine. |
| 700 | 1 |
_aEvgenov, Oleg V. _eeditor. |
|
| 700 | 1 |
_aStasch, Johannes-Peter. _eeditor. |
|
| 710 | 2 | _aSpringerLink (Online service) | |
| 773 | 0 | _tSpringer eBooks | |
| 776 | 0 | 8 |
_iPrinted edition: _z9783642386633 |
| 830 | 0 |
_aHandbook of Experimental Pharmacology, _x0171-2004 ; _v218 |
|
| 856 | 4 | 0 | _uhttp://dx.doi.org/10.1007/978-3-642-38664-0 |
| 912 | _aZDB-2-SBL | ||
| 999 |
_c98307 _d98307 |
||